Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Date:11/20/2007

Ph.D., Executive Vice President, Chief Scientific Officer and President, Research and Development, Bristol-Myers Squibb. "This approval is a reflection of our ongoing commitment to provide innovative therapies, such as ABILIFY, to help adults living with depression."

"We are pleased that ABILIFY has achieved this important milestone as the first medication approved as adjunctive treatment for adults with major depressive disorder," said Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer, Otsuka Pharmaceutical Development and Commercialization, Inc. "This new add-on treatment option for depression represents hope for many adults suffering from this debilitating illness."

Major depressive disorder affects millions of U.S. adults at some point in their lives.(2) A recent study evaluated different treatment approaches, including adjunctive medications and switching strategies, in patients with MDD.(1) The study found that 63 percent of patients did not achieve adequate relief of depressive symptoms following the initial treatment with an antidepressant alone.(1) Additionally, the study demonstrated that the use of adjunctive medications in treatment may be useful to improve unresolved depressive symptoms.(1)

Clinical Trial Design and Findings

Two six-week, double-blind, randomized, placebo-controlled, multicenter studies evaluated the efficacy and safety of add-on ABILIFY in adult patients with a primary diagnosis of major depressive disorder who had experienced an inadequate response to prior antidepressant therapy (one to three courses) in the current episode.

After an eight-week prospective treatment phase with one ADT plus single- blind placebo to confirm inadequate response to ADT, 743 participants entered a six-week randomized treatment phase during which they continued their ADT plus double-blind adjunctive placebo or adjunctive ABILIFY. All study participants received one of the commonly prescribed
'/>"/>

SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
9. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 DuPont Pioneer and ... more than double the acreage contracted for Plenish® ... its soybean crush facility in Salisbury, Md. The ... will target several markets including foodservice and food ... performance. , For the 2015 growing season, Perdue ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 Today, Nerium ... announced the winners of its “Reflect Your Youth” contest, ... not only seen a difference in their skin since ... a new outlook on life as a result of ... originated as an effort by Nerium International to inspire ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... article, the City of Milwaukee has negotiated a three-year "franchise-like" ... company to start an Internet protocol video service to compete ... will be considered by the Milwaukee Common Council, AT&T would ... by the service. , , While there are ...
... big business (untold billions of dollars every year), they also ... of the fundamental ethical principle of informed consent ... is that conducting a clinical trial carries with it the ... positive or negative or even if the clinical trial is ...
... For the second time this year, a tech-based company in ... to the public. Called an initial public offering, this kind ... and investors who are directly involved, but to others who ... Madison-based biotechnology company, has filed papers with the Securities ...
Cached Biology Technology:State video franchises vs. universal service: Grasping the total picture 2State video franchises vs. universal service: Grasping the total picture 3State video franchises vs. universal service: Grasping the total picture 4What patients want: A story of choice, clinical trials & evidence-based medicine 2What patients want: A story of choice, clinical trials & evidence-based medicine 3What patients want: A story of choice, clinical trials & evidence-based medicine 4What patients want: A story of choice, clinical trials & evidence-based medicine 5Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3
(Date:10/22/2014)... The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia ... (AFRL), has chosen a project proposed by the Arizona ... Arizona College of Medicine – Tucson ... is to assess different sweat collection methods and devices ... under a variety of human-body conditions, the results of ...
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... The next time you are stung by a ... venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs ... or diagnose cancer. This research, described in the August ... ( http://www.fasebj.org ), shows how modified melittin may revolutionize ...
... by which Helicobacter pylori , the only known cancer-causing ... The new study, in the journal Oncogene , reports ... pylori infection and stomach cancer, the second leading cause ... population is infected with H. pylori, a bacterium that can ...
... genomes that potentially hide a rich array of pharmaceutical ... antibiotic. The study, reported in the August issue of ... serious diseases that are rapidly acquiring multi-drug resistance. ... successfully used a ,genome mining, approach to find and ...
Cached Biology News:Cancer-causing bacterium targets tumor-suppressor protein 2Cancer-causing bacterium targets tumor-suppressor protein 3Mining bacterial genomes reveals valuable 'hidden' drugs 2
Ets-1...
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: